Pomalyst (Pomalidomide)

Brand Name

Pomalyst

Generic Name

Pomalidomide

View Brand Information

FDA approval date: February 18, 2013

Classification: Thalidomide Analog

Form: Capsule

What is Pomalyst (Pomalidomide)?

POMALYST is a thalidomide analogue indicated for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug, Device

Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.

A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Enrollment Status: Recruiting

Publish Date: June 16, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the p...

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

Who is this study for: Patients with Plasma Cell Myeloma

Enrollment Status: Recruiting

Publish Date: June 16, 2026

Intervention Type: Drug

Study Drugs: Isatuximab SAR650984, Dexamethasone, Pomalidomide, SAR439459

Study Phase: Phase 1/Phase 2

Summary: The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

View All Clinical Trials

Related Latest Advances

Rational design, molecular characterization and dissociation mechanisms of PROTACs targeting hFAAH.

Journal: Physical chemistry chemical physics : PCCP

Published: June 23, 2026

Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 17, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

View All Latest Advances